Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 3;112(4):793-807.
doi: 10.1016/j.ajhg.2025.02.018. Epub 2025 Mar 14.

Actionable genetic variants in 4,198 Scottish participants from the Orkney and Shetland founder populations and implementation of return of results

Affiliations

Actionable genetic variants in 4,198 Scottish participants from the Orkney and Shetland founder populations and implementation of return of results

Shona M Kerr et al. Am J Hum Genet. .

Abstract

The benefits of returning clinically actionable genetic results to participants in research cohorts are accruing, yet such a genome-first approach is challenging. Here, we describe the implementation of return of such results in two founder populations from Scotland. Between 2005 and 2015, we recruited >4,000 adults with grandparents from Orkney and Shetland into the Viking Genes research cohort. The return of genetic data was not offered at baseline, but in 2023, we sent invitations to participants for consent to return of actionable genetic findings. We generated exome sequence data from 4,198 participants and used the American College of Medical Genetics and Genomics (ACMG) v.3.2 list of 81 genes, ClinVar review, and pathogenicity status, plus manual curation, to develop a pipeline to identify potentially actionable variants. We identified 104 individuals (2.5%) with 108 actionable genotypes at 39 variants in 23 genes and validated these. Working with the NHS Clinical Genetics service, which provided genetic counseling and clinical verification of the research results, and after expert clinical review, we notified 64 consenting participants (or their next of kin) of their actionable genotypes. Ten actionable variants across seven genes (BRCA1, BRCA2, ATP7B, TTN, KCNH2, MUTYH, and GAA) have risen 50- to >3,000-fold in frequency through genetic drift in ancestral island localities. Viking Genes is one of the first UK research cohorts to return actionable findings, providing an ethical and logistical exemplar of return of results. The genetic structure in the Northern Isles of Scotland with multiple founder effects provides a unique opportunity for a tailored approach to disease prevention through genetic screening.

Keywords: Orkney; Shetland; actionable variant; exomes; founder effect; return of results.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests A.R.S. and G.T. are employees and/or stockholders of Regeneron Genetics Center or Regeneron Pharmaceuticals. L.K. is an employee of BioAge Labs and holds share options. J.S.W. has received research support from Bristol Myers Squibb and has acted as a consultant for MyoKardia, Pfizer, Foresite Labs, Health Lumen, and Tenaya Therapeutics.

Figures

Figure 1
Figure 1
Isles and parishes of Orkney and Shetland Each archipelago consists of a larger island called the Mainland, with surrounding smaller isles. Both island groups can be divided into 4–6 larger areas, such as West Shetland (known locally as the West side) or the West Mainland of Orkney, which in turn are organized into 25 parishes or isles. Founder effects are usually concentrated in one parish/isle or in one of the larger contiguous areas. W&W, Whiteness & Weisdale; Tin, Tingwall; Ler, Lerwick; St A, St. Andrews; K&StO, Kirkwall & St. Ola; Orp, Orphir; Ste, Stenness; Str, Stromness; San, Sandwick (Orkney); Bir, Birsay; Evi, Evie; Ren, Rendall; Fir, Firth; Har, Harray.
Figure 2
Figure 2
Overview of Viking Genes return of results Processes implemented by the Viking Genes research team are boxed with no shading; processes implemented by the NHS clinical team are shaded. PIS, participant information sheet (see supplemental information).

Similar articles

References

    1. Miller D.T., Lee K., Abul-Husn N.S., Amendola L.M., Brothers K., Chung W.K., Gollob M.H., Gordon A.S., Harrison S.M., Hershberger R.E., et al. ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG) Genet. Med. 2023;25 doi: 10.1016/j.gim.2023.100866. - DOI - PMC - PubMed
    1. Van Hout C.V., Tachmazidou I., Backman J.D., Hoffman J.D., Liu D., Pandey A.K., Gonzaga-Jauregui C., Khalid S., Ye B., Banerjee N., et al. Exome sequencing and characterization of 49,960 individuals in the UK Biobank. Nature. 2020;586:749–756. doi: 10.1038/s41586-020-2853-0. - DOI - PMC - PubMed
    1. Venner E., Muzny D., Smith J.D., Walker K., Neben C.L., Lockwood C.M., Empey P.E., Metcalf G.A., Kachulis C., et al. All of Us Research Program Regulatory Working Group Whole-genome sequencing as an investigational device for return of hereditary disease risk and pharmacogenomic results as part of the All of Us Research Program. Genome Med. 2022;14:34. doi: 10.1186/s13073-022-01031-z. - DOI - PMC - PubMed
    1. Schwartz M.L.B., McCormick C.Z., Lazzeri A.L., Lindbuchler D.M., Hallquist M.L.G., Manickam K., Buchanan A.H., Rahm A.K., Giovanni M.A., Frisbie L., et al. A Model for Genome-First Care: Returning Secondary Genomic Findings to Participants and Their Healthcare Providers in a Large Research Cohort. Am. J. Hum. Genet. 2018;103:328–337. doi: 10.1016/j.ajhg.2018.07.009. - DOI - PMC - PubMed
    1. Lewis A.C.F., Knoppers B.M., Green R.C. An international policy on returning genomic research results. Genome Med. 2021;13:115. doi: 10.1186/s13073-021-00928-5. - DOI - PMC - PubMed